GLP‐1RA‐induced delays in gastrointestinal motility: Predicted effects on coadministered drug absorption by PBPK analysis
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2025-04 · 45 (4) · 211-219
DOI: 10.1002/phar.70007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, online erschienen am 23.02.2025. Verfasst von Levi Hooper und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Gastrointestinal Motility, Models, Biological, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
Background
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are breakthrough medicines for obesity treatment and have rapidly gained widespread clinical application. Although GLP‐1RAs are generally not associated with drug–drug interactions (DDIs) via drug metabolism or transporter pathways, their effects on reduced gastrointestinal (GI) motility could influence the pharmacokinetics of coadministered oral medications.
Objectives
This study uses physiologically based pharmacokinetic (PBPK) modeling to evaluate the DDI potential of GLP‐1RA‐induced GI motility delays.
Methods
Using Certara's Simcyp™ Simulator V23, we modeled the pharmacokinetics of atorvastatin, metformin, metoprolol, ethinyl estradiol, and digoxin in a virtual cohort of obese adults ( n = 1000). GLP‐1RA‐related gastric emptying delays were simulated based on capsule endoscopy data from liraglutide‐treated patients. Results were compared with clinical data from semaglutide and liraglutide users. Additionally, exploratory analyses were conducted on frequently coadministered drugs identified from the 2022 Medical Expenditure Panel Survey, including rosuvastatin and dabigatran.
Results
GLP‐1RA‐induced gastric emptying delays led to increased area under the concentration–time curve (AUC) and prolonged time to maximum concentration (Tmax) for several medications. The model outputs for rosuvastatin, valsartan, and dabigatran indicate increases in AUC by 64%, 90%, and 205%, respectively. Dabigatran, a narrow therapeutic index anticoagulant, exhibited the most significant changes, raising potential concerns of higher drug exposure.
Conclusions
PBPK modeling suggests that GLP‐1RAs can influence the pharmacokinetics of oral medications by delaying gastric emptying, potentially leading to clinically relevant DDIs. While further clinical validation and pharmacovigilance is needed, these findings highlight the importance of PBPK tools in predicting and potentially mitigating risks associated with GLP‐1RA use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.
ORCID-Profile: Levi Hooper, Shuhan Liu, Manjunath P Pai
Förderung
- NIDDK NIH HHS
- NCATS NIH HHS
- National Center for Advancing Translational Sciences
Zitieren
APA
Hooper, L., Liu, S., & Pai, M. P. (2025). GLP‐1RA‐induced delays in gastrointestinal motility: Predicted effects on coadministered drug absorption by PBPK analysis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 45(4), 211-219. https://doi.org/10.1002/phar.70007
Vancouver
Hooper L, Liu S, Pai MP. GLP‐1RA‐induced delays in gastrointestinal motility: Predicted effects on coadministered drug absorption by PBPK analysis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2025;45(4):211-219. doi:10.1002/phar.70007
BibTeX
@article{Hooper2025,
author = {Hooper, Levi and Liu, Shuhan and Pai, Manjunath P},
title = {GLP‐1RA‐induced delays in gastrointestinal motility: Predicted effects on coadministered drug absorption by PBPK analysis},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2025},
volume = {45},
number = {4},
pages = {211--219},
doi = {10.1002/phar.70007}
}
EUVIMED